KR20160075819A - 선택적 pyy 화합물 및 그것의 사용 - Google Patents

선택적 pyy 화합물 및 그것의 사용 Download PDF

Info

Publication number
KR20160075819A
KR20160075819A KR1020167015805A KR20167015805A KR20160075819A KR 20160075819 A KR20160075819 A KR 20160075819A KR 1020167015805 A KR1020167015805 A KR 1020167015805A KR 20167015805 A KR20167015805 A KR 20167015805A KR 20160075819 A KR20160075819 A KR 20160075819A
Authority
KR
South Korea
Prior art keywords
ethoxy
amino
seq
acetyl
hpyy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167015805A
Other languages
English (en)
Korean (ko)
Inventor
쇠렌 외스터가르드
킬리안 발더마르 콘데 프리뵈스
비르기트 비초렉
옌스 카알비 톰센
비르기테 쉬엘레루프 불프
카르스텐 옌센
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20160075819A publication Critical patent/KR20160075819A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
KR1020167015805A 2013-11-15 2014-11-13 선택적 pyy 화합물 및 그것의 사용 Withdrawn KR20160075819A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP13193082.8 2013-11-15
EP13193082 2013-11-15
US201361906020P 2013-11-19 2013-11-19
US61/906,020 2013-11-19
EP14176725.1 2014-07-11
EP14176725 2014-07-11
PCT/EP2014/074476 WO2015071355A1 (en) 2013-11-15 2014-11-13 Selective pyy compounds and uses thereof

Publications (1)

Publication Number Publication Date
KR20160075819A true KR20160075819A (ko) 2016-06-29

Family

ID=53056816

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015805A Withdrawn KR20160075819A (ko) 2013-11-15 2014-11-13 선택적 pyy 화합물 및 그것의 사용

Country Status (15)

Country Link
US (2) US9085637B2 (enExample)
EP (1) EP3068421B1 (enExample)
JP (1) JP6602760B2 (enExample)
KR (1) KR20160075819A (enExample)
CN (1) CN105722526B (enExample)
AU (1) AU2014350197B2 (enExample)
BR (1) BR112016010383A2 (enExample)
CA (1) CA2929672A1 (enExample)
IL (1) IL245045B (enExample)
MX (1) MX369818B (enExample)
PL (1) PL3068421T3 (enExample)
RS (1) RS59026B1 (enExample)
SI (1) SI3068421T1 (enExample)
TW (1) TWI661835B (enExample)
WO (1) WO2015071355A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180019616A (ko) * 2015-06-12 2018-02-26 노보 노르디스크 에이/에스 선택적인 pyy 화합물 및 그것의 사용

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012080471A1 (en) 2010-12-16 2012-06-21 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
MY171146A (en) 2012-03-22 2019-09-27 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
CN105263957A (zh) * 2013-05-02 2016-01-20 葛兰素史克知识产权开发有限公司 治疗肽
PT2991671T (pt) 2013-05-02 2018-11-05 Novo Nordisk As Dosagem oral de compostos de glp-1
KR20160075819A (ko) 2013-11-15 2016-06-29 노보 노르디스크 에이/에스 선택적 pyy 화합물 및 그것의 사용
WO2015071356A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
WO2017186896A1 (en) * 2016-04-28 2017-11-02 Novo Nordisk A/S Semaglutide in cardiovascular conditions
WO2018083335A1 (en) 2016-11-07 2018-05-11 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
MA49617A (fr) 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
HRP20240485T1 (hr) 2017-08-24 2024-07-05 Novo Nordisk A/S Pripravci glp-1 i njihova upotreba
US20210171598A1 (en) 2017-12-01 2021-06-10 University Of Copenhagen Peptide hormone with one or more o-glycans
CA3087077A1 (en) * 2018-01-09 2019-07-18 Gila Therapeutics, Inc. Compositions and methods for treating metabolic diseases
MA53076B1 (fr) 2018-02-02 2023-11-30 Novo Nordisk As Compositions solides comportant un agoniste glp-1, du sel d'acide n-(8-(2-hydroxybenzoyl)amino)caprylate et un lubrifiant
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
EP4009957B1 (en) * 2019-08-07 2023-10-11 Novo Nordisk A/S Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN114641303A (zh) 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂
IL300239A (en) 2020-08-07 2023-03-01 Boehringer Ingelheim Int Soluble NPY2 receptor agonists
EP4240749A1 (en) * 2020-11-09 2023-09-13 Embark Biotech ApS Compounds and their use in treatment of tachykinin receptor mediated disorders
CN119677527A (zh) 2022-08-18 2025-03-21 勃林格殷格翰国际有限公司 包含长效glp-1/胰高血糖素及npy2受体激动剂的组合疗法
WO2025128624A2 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a substituted tryptophan residue or a terminal substituent
TW202540152A (zh) * 2023-12-12 2025-10-16 美商卡默療法股份有限公司 具有經修飾之離胺酸殘基之雜合肽化合物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ265452A (en) 1993-03-29 1997-09-22 Univ Cincinnati Analogues of peptide yy, dimers and pharmaceutical compositions
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
WO1998020885A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
JP2002517483A (ja) 1998-06-08 2002-06-18 シェーリング コーポレイション 神経ペプチドｙ５レセプターアンタゴニスト
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
RU2275207C2 (ru) 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
IL160983A0 (en) 2001-09-24 2004-08-31 Imp College Innovations Ltd Use of pyy for preparation of a medicament for modification of feeding behavior
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1583549A4 (en) 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
JP2007537981A (ja) 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
EP2932981B1 (en) 2003-09-19 2021-06-16 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
IN2012DN03921A (enExample) 2004-02-11 2015-09-04 Amylin Pharmaceuticals Inc
WO2005077094A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
MXPA06010347A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y2 para intervenciones terapeuticas.
EP1786458A2 (en) 2004-03-17 2007-05-23 7TM Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
CN1933848A (zh) 2004-03-17 2007-03-21 7Tm制药联合股份有限公司 用于治疗性干预的y2选择性受体激动剂
CA2560174A1 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
BRPI0512988A (pt) 2004-07-08 2008-04-22 Novo Nordisk As método para aumentar a meia-vida plasmática de uma molécula, composto, uso do mesmo, e, composição farmacêutica
US7994119B2 (en) 2004-07-19 2011-08-09 University Of Cincinnati Compounds for control of appetite
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP2009500453A (ja) 2005-07-11 2009-01-08 ナステック ファーマスーティカル カンパニー インク． 向上されたｐｙｙの粘膜送達用製剤
KR20080031414A (ko) 2005-07-18 2008-04-08 노보 노르디스크 에이/에스 비만치료에 사용하기 위한 신규 펩티드
JP2009508886A (ja) 2005-09-21 2009-03-05 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ２選択性レセプターアゴニスト
AU2005337116A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
AU2006324076A1 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
WO2007068718A1 (en) 2005-12-14 2007-06-21 Novo Nordisk A/S Polypeptide protracting tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
JP5412273B2 (ja) 2006-03-21 2014-02-12 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー ペプチド−ぺプチダーゼ阻害剤及びその使用
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20100016237A1 (en) 2007-01-18 2010-01-21 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
EP2167535A2 (en) 2007-07-09 2010-03-31 Imperial Innovations Limited Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
JP5606314B2 (ja) 2007-09-05 2014-10-15 ノボ・ノルデイスク・エー／エス Ａ−ｂ−ｃ−ｄ−で誘導体化されたペプチドとその治療用途
AU2008303910A1 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of stresscopin-related peptide as a therapeutic agent
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
KR20110017874A (ko) 2008-05-16 2011-02-22 노보 노르디스크 에이/에스 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
MX2011004427A (es) 2008-11-05 2011-05-31 Hoffmann La Roche Agonistas del receptor de neuropeptido-2 (y-2r) y usos de los mismos.
UA102432C2 (ru) 2009-02-20 2013-07-10 Іпсен Фарма С.А.С. Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
WO2011033068A1 (en) 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011045232A2 (en) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
JP2013510829A (ja) 2009-11-13 2013-03-28 ノヴォ ノルディスク アー／エス 長時間作用型ｙ２受容体アゴニスト
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
ES2935300T3 (es) * 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
US20150141336A1 (en) 2012-05-29 2015-05-21 Novo Nordisk A/S Pancreatic Peptide Compounds and Use
CN105263957A (zh) 2013-05-02 2016-01-20 葛兰素史克知识产权开发有限公司 治疗肽
KR20160075819A (ko) 2013-11-15 2016-06-29 노보 노르디스크 에이/에스 선택적 pyy 화합물 및 그것의 사용
WO2015071356A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
EP3307768B1 (en) * 2015-06-12 2025-01-29 Novo Nordisk A/S Selective pyy compounds and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180019616A (ko) * 2015-06-12 2018-02-26 노보 노르디스크 에이/에스 선택적인 pyy 화합물 및 그것의 사용

Also Published As

Publication number Publication date
CA2929672A1 (en) 2015-05-21
CN105722526A (zh) 2016-06-29
US10246497B2 (en) 2019-04-02
AU2014350197A1 (en) 2016-05-05
US20160289283A1 (en) 2016-10-06
SI3068421T1 (sl) 2019-08-30
TWI661835B (zh) 2019-06-11
JP6602760B2 (ja) 2019-11-06
AU2014350197B2 (en) 2018-10-04
US9085637B2 (en) 2015-07-21
WO2015071355A1 (en) 2015-05-21
IL245045A0 (en) 2016-05-31
MX369818B (es) 2019-11-22
IL245045B (en) 2019-09-26
CN105722526B (zh) 2020-12-08
TW201605467A (zh) 2016-02-16
JP2017505284A (ja) 2017-02-16
PL3068421T3 (pl) 2019-11-29
EP3068421B1 (en) 2019-04-17
BR112016010383A2 (pt) 2017-12-05
RS59026B1 (sr) 2019-08-30
MX2016006053A (es) 2016-08-17
EP3068421A1 (en) 2016-09-21
US20150152150A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
EP3068421B1 (en) Selective pyy compounds and uses thereof
KR102476550B1 (ko) 선택적인 pyy 화합물 및 그것의 사용
EP3068795B1 (en) Hpyy(1-36) having a beta-homoarginine substitution at position 35
WO2016124687A1 (en) Selective pyy compounds and uses thereof
TW201629095A (zh) 穩定的基於ｇｌｐ－１之ｇｌｐ－１／升糖素受體共促效劑
RU2678312C1 (ru) Селективные соединения пептида yy и их применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160614

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191001

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20200128

WITB Written withdrawal of application